PCM
BEAT

Palisade Capital Management’s BioTelemetry, Inc. BEAT Stock Holding History

Palisade Capital Management’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-542,118
Closed -$39.1M – 405
2020
Q4 		$39.1M Sell
542,118
-21,480
-4% -$1.12M 1% 15
2020
Q3 		$25.7M Buy
563,598
+177,654
+46% +$7.43M 0.76% 28
2020
Q2 		$17.4M Buy
385,944
+8,884
+2% +$398K 0.55% 57
2020
Q1 		$14.5M Buy
377,060
+15,284
+4% +$704K 0.51% 59
2019
Q4 		$16.8M Buy
361,776
+19,826
+6% +$859K 0.47% 70
2019
Q3 		$13.9M Buy
341,950
+55,498
+19% +$2.4M 0.43% 79
2019
Q2 		$13.8M Buy
286,452
+52,791
+23% +$2.78M 0.43% 79
2019
Q1 		$14.6M Buy
233,661
+10,743
+5% +$738K 0.47% 70
2018
Q4 		$13.3M Sell
222,918
-74,633
-25% -$4.48M 0.49% 60
2018
Q3 		$19.2M Sell
297,551
-94,501
-24% -$5.27M 0.53% 60
2018
Q2 		$17.6M Buy
392,052
+70,188
+22% +$2.8M 0.51% 64
2018
Q1 		$9.99M Sell
321,864
-2,939
-0.9% -$96.7K 0.34% 100
2017
Q4 		$9.71M Buy
+324,803
New +$9.4M 0.33% 101

Other funds holding BEAT

LCM
Logan Capital Management Newtown Square, Pennsylvania $2.69B AUM 46.33% 1-Year Est. Return

Palisade Capital Management's BEAT Position: Q1 2021 in Review

Palisade Capital Management sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 542,118 shares — an estimated $39.1M sold.

Palisade Capital Management first reported a position in BEAT in Q4 2017 and held it in 13 quarters. The position peaked at $39.1M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

  • Palisade Capital Management reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
  • Palisade Capital Management sold 542,118 BioTelemetry, Inc. shares in Q1 2021, an estimated $39.1M.
  • Palisade Capital Management first reported a position in BioTelemetry, Inc. in Q4 2017 and held it in 13 quarters.
  • Palisade Capital Management's BioTelemetry, Inc. position peaked at $39.1M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Palisade Capital Management's 13F filing for Q1 2021, filed 12 May 2021.